Athira Pharma, Inc. (ATHA)

1,9200 -0,0900 (-4,48 %) À la clôture : 04:00PM EDT

Athira Pharma, Inc.

18706 North Creek Parkway
Suite 104
Bothell, WA 98011
United States
425 620 8501
https://www.athira.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 65

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Mark J. Litton M.B.A., Ph.D.	President, CEO & Director	882,7k	S.O.	1968
Mr. Andrew W. Gengos	CFO & Chief Business Officer	396,16k	S.O.	1964
Ms. Rachel P. Lenington M.B.A.	Chief Development Officer & COO	578k	S.O.	1973
Dr. Kevin Church Ph.D.	Chief Scientific Officer	123,67k	S.O.	1985
Ms. Julie Rathbun	Head of Investor Relations	S.O.	S.O.	S.O.
Mr. Mark F. Worthington J.D.	General Counsel & Corporate Secretary	503,83k	S.O.	1966
Ms. Samantha Willing	Chief People Officer	S.O.	S.O.	S.O.
Dr. Javier San Martin M.D.	Chief Medical Officer	S.O.	S.O.	1965

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Athira Pharma, Inc. en date du 1 avril 2024 est 7. Les scores principaux sont Audit : 7; Société : 5; Droits des actionnaires : 8; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.